Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells

Prolonged Antitumor NK Cell Reactivity Elicited by CXCL10-Expressing Dendritic Cells Licensed by CD40L+CD4+ Memory T Cells

(2011) K. Shimizu et al.   JOURNAL OF IMMUNOLOGY

Innate or Adaptive Immunity? The Example of Natural Killer Cells

(2011) E. Vivier et al.   SCIENCE

Natural Killer Cell Education and Tolerance

(2010) Mark T. Orr et al.   CELL

Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6

(2009) R. E. Tiedemann et al.   BLOOD

The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors

(2009) Michael Hedvat et al.   CANCER CELL

The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies

(2009) J. Ozao-Choy et al.   CANCER RESEARCH

The Kinase Inhibitors Sunitinib and Sorafenib Differentially Affect NK Cell Antitumor Reactivity In Vitro

(2009) M. Krusch et al.   JOURNAL OF IMMUNOLOGY

RNAi screening: tips and techniques

(2009) Sonia Sharma et al.   NATURE IMMUNOLOGY

Dasatinib suppresses in vitro natural killer cell cytotoxicity

(2008) S. J. Blake et al.   BLOOD

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

(2008) M. M. Hipp et al.   BLOOD

Human natural killer cells

(2008) M. A. Caligiuri   BLOOD

CDK8 is a colorectal cancer oncogene that regulates β-catenin activity

(2008) Ron Firestein et al.   NATURE

Up on the tightrope: natural killer cell activation and inhibition

(2008) Lewis L Lanier   NATURE IMMUNOLOGY